• Join the mission

    Get your patients involved

  • Join the mission

    Get your patients involved

  • Join the mission

    Get your patients involved

  • Join the mission

    Get your patients involved

  • Join the mission

    Get your patients involved

MissionAD is a clinical research program testing an investigational drug for the early stages of Alzheimer’s disease.3,4

Now in Phase III, MissionAD is currently enrolling and adding clinical sites.

We’re recruiting, qualifying participants must:

Be 50 to 85 years of age
Be experiencing noticeable changes in memory or thinking
Have a study partner available
Test positive or have tested positive for the presence of amyloid in the brain

To enroll patients in MissionAD or become a program investigator, get in touch with us today.

What is MissionAD?

This clinical research program will explore the role of BACE (beta-site amyloid precursor protein cleaving enzyme) inhibition in Alzheimer’s disease.

Inhibition of BACE reduces amyloid beta production, which is thought to lead to a reduction in amyloid plaque formations caused by the aggregation of toxic amyloid oligomers and protofibrils in the brain. It’s believed that decreasing the formation of these plaques may potentially slow Alzheimer’s disease progression.5

Stay in touch

I agree with the Terms of Information Use below

Come back and visit us, or get email updates when new information is available.

Our commitment

Eisai is at the forefront of researching new strategies for the earlier diagnosis and treatment of Alzheimer’s disease and other forms of dementia.

We have a strong legacy in neurology as a human health care company and global pharmaceutical organization. Committed to discovering and developing innovative therapies for unmet patient needs, we established the Neurology Business Group in 2016, comprising all functions relating to drug discovery research and clinical research.

Learn more

MissionAD on ClinicalTrials.gov

Research & Development at Eisai

References

1. World Health Organization. Dementia Fact Sheet. May 2017. http://who.int/mediacentre/factsheets/fs362/en/. Accessed June 22, 2017.

2. Alzheimer’s Association. May 2014. http://alz.org/global/. Accessed June 22, 2017.

3. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD1). https://clinicaltrials.gov/ct2/show/NCT02956486. Accessed June 22, 2017.

4. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD2). https://clinicaltrials.gov/ct2/show/NCT03036280. Accessed June 22, 2017.

5. Vassar, R. BACE1 Inhibitor Drugs in Clinical Trials for Alzheimer’s Disease. Alzheimer's Research & Therapy:2014;6.89:1-14.

6. Alzheimer's Association. Mild Cognitive Impairment (MCI): Signs, Symptoms, & Diagnosis. May 2017. http://www.alz.org/dementia/mild-cognitive-impairment-mci.asp. Accessed June 22, 2017.

7. Alzheimer's Association. What Is Alzheimer's? May 2017. http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed June 22, 2017.

8. Alzheimer's Association. Stages of Alzheimer's & Symptoms. June 2017. http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp#mild. Accessed June 22, 2017.

9. Alzheimer's Association. Why Get Checked. June 2017. http://www.alz.org/alzheimers_disease_why_get_checked.asp. Accessed June 22, 2017.

10. Alzheimer's Association. Alzheimer’s and Dementia Testing for Earlier Diagnosis. June 2017. http://alz.org/research/science/earlier_alzheimers_diagnosis.asp. Accessed June 22, 2017.

11. National Institutes of Health. What Are Clinical Trials? May 2017. https://www.nhlbi.nih.gov/studies/clinicaltrials. Accessed June 22, 2017.